Literature DB >> 3377438

Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type.

J R Atack1, C May, J A Kaye, A D Kay, S I Rapoport.   

Abstract

Protein concentration and acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities were assayed in the cerebrospinal fluid (CSF) of 26 healthy normal subjects (20-86 years old), 27 patients with dementia of the Alzheimer type (DAT), and 10 patients with dementia of the Alzheimer type with extrapyramidal signs (EDAT). In normal subjects, there was an age-related increase in CSF protein and AChE activity and a significant correlation (p less than 0.001) between CSF protein and BChE activity. In the DAT and EDAT groups, CSF AChE activities (mean +/- SD = 17.5 +/- 3.6 and 15.3 +/- 4.4 nmol/min/ml, respectively) were significantly lower (p less than 0.05) than in 13 age-matched control subjects (21.5 +/- 5.6 nmol/min/ml). In contrast, neither CSF protein concentration, BChE activity, nor the ratio of AChE/BChE differed significantly between groups. In patients with DAT, CSF AChE activity was significantly lower (p less than 0.05) in subjects with an early onset compared to those with a late onset (16.4 +/- 3.4 and 19.7 +/- 2.8 nmol/min/ml, respectively), and activity in the latter group did not differ significantly from control values. CSF AChE activity was not related to dementia severity and did not change significantly over an 18-month period. Although these results confirm a cholinergic deficit in patients with DAT, the considerable overlap of CSF AChE activity between groups and the nonsignificant correlation between AChE activity and dementia severity limit the usefulness of CSF AChE as a diagnostic marker of this disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377438     DOI: 10.1002/ana.410230209

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  A long-term follow-up study of cerebrospinal fluid acetylcholinesterase in delirium.

Authors:  H J Koponen; J Sirviö; U Lepola; E Leinonen; P J Riekkinen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

2.  Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase.

Authors:  A S Balasubramanian
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

3.  Elevated cerebrospinal fluid proteins in sciatica caused by disc herniation.

Authors:  J S Skouen; J L Larsen; E Vollset; M Grønning
Journal:  Eur Spine J       Date:  1994       Impact factor: 3.134

4.  Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.

Authors:  J R Atack; I Litvan; L J Thal; C May; S I Rapoport; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

5.  The molecular forms of acetylcholinesterase in cerebrospinal fluid of normal subjects--effect of aging.

Authors:  J Sirviö; Z Rakonczay; P Hartikainen; P Kasa; P J Riekkinen
Journal:  J Neural Transm Gen Sect       Date:  1991

6.  A cluster of HTLV-1 associated tropical spastic paraparesis in Equateur (Zaire): ethnic and familial distribution.

Authors:  K Kayembe; P Goubau; J Desmyter; R Vlietinck; H Carton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-01       Impact factor: 10.154

7.  Acetylcholinesterase assay for cerebrospinal fluid using bupivacaine to inhibit butyrylcholinesterase.

Authors:  W H Kluge; H H Kluge; H I Bauer; S Pietsch; J Anders; R A Venbrocks
Journal:  BMC Biochem       Date:  2001-12-21       Impact factor: 4.059

8.  Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease.

Authors:  Per Johansson; Erik G Almqvist; Jan-Ove Johansson; Niklas Mattsson; Ulf Andreasson; Oskar Hansson; Anders Wallin; Kaj Blennow; Henrik Zetterberg; Johan Svensson
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

9.  Global loss of acetylcholinesterase activity with mitochondrial complexes inhibition and inflammation in brain of hypercholesterolemic mice.

Authors:  Rajib Paul; Anupom Borah
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

10.  Altered levels of acetylcholinesterase in Alzheimer plasma.

Authors:  María-Salud García-Ayllón; Iolanda Riba-Llena; Carol Serra-Basante; Jordi Alom; Rathnam Boopathy; Javier Sáez-Valero
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.